Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), presents a poster today titled: A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation at the 2019 International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Nice, France.

The poster will present findings from the completed Phase 1 trial of leading drug candidate PBT434. The drug was found to be safe and well tolerated in its first-in-human study for the treatment of atypical Parkinsonian disorders such as Multiple Systems Atrophy (MSA).

The study recruited 70 adult volunteers and ten older adult (or ≥65 year old) volunteers who took single ascending and multiple ascending oral doses. The volunteers in the single ascending dose, made up of four cohorts, received progressively higher single oral doses of PBT434 followed by blood sampling over 72 hours. In the multiple ascending dose, volunteers received eight days dosing with PBT434, administered as three successively higher dose levels.

Importantly, the results indicated that PBT434 not only crosses the blood brain barrier in humans, confirming previous observations in animal studies, but that clinically tested doses achieve concentrations in the brain that were comparable to or exceeded those associated with efficacy in animal models of disease.

David Stamler, MD, Chief Medical Officer & Senior VP Clinical Development of Alterity, will be presenting the poster. “PBT434 could be transformational for atypical Parkinsonian disorders, improving the lives of those who suffer from these debilitating diseases.” said Dr. Stamler.

END

Investor enquiries IR@alteritytherapeutics.com